Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Thrombus Migration and Fragmentation After Intravenous Alteplase Treatment: The INTERRSeCT Study

T. Ohara, BK. Menon, FS. Al-Ajlan, M. Horn, M. Najm, A. Al-Sultan, J. Puig, D. Dowlatshahi, AI. Calleja Sanz, SI. Sohn, SH. Ahn, AY. Poppe, R. Mikulik, N. Asdaghi, TS. Field, A. Jin, T. Asil, JM. Boulanger, F. Letteri, S. Dey, JW. Evans, M....

. 2021 ; 52 (1) : 203-212. [pub] 20201215

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21019598

Grantová podpora
CIHR - Canada

BACKGROUND AND PURPOSE: There is interest in what happens over time to the thrombus after intravenous alteplase. We study the effect of alteplase on thrombus structure and its impact on clinical outcome in patients with acute stroke. METHODS: Intravenous alteplase treated stroke patients with intracranial internal carotid artery or middle cerebral artery occlusion identified on baseline computed tomography angiography and with follow-up vascular imaging (computed tomography angiography or first run of angiography before endovascular therapy) were enrolled from INTERRSeCT study (Identifying New Approaches to Optimize Thrombus Characterization for Predicting Early Recanalization and Reperfusion With IV Alteplase and Other Treatments Using Serial CT Angiography). Thrombus movement after intravenous alteplase was classified into complete recanalization, thrombus migration, thrombus fragmentation, and no change. Thrombus migration was diagnosed when occlusion site moved distally and graded according to degrees of thrombus movement (grade 0-3). Thrombus fragmentation was diagnosed when a new distal occlusion in addition to the primary occlusion was identified on follow-up imaging. The association between thrombus movement and clinical outcome was also evaluated. RESULTS: Among 427 patients in this study, thrombus movement was seen in 54% with a median time of 123 minutes from alteplase administration to follow-up imaging, and sub-classified as marked (thrombus migration grade 2-3 + complete recanalization; 27%) and mild to moderate thrombus movement (thrombus fragmentation + thrombus migration grade 0-1; 27%). In patients with proximal M1/internal carotid artery occlusion, marked thrombus movement was associated with a higher rate of good outcome (90-day modified Rankin Scale, 0-2) compared with mild to moderate movement (52% versus 27%; adjusted odds ratio, 5.64 [95% CI, 1.72-20.10]). No difference was seen in outcomes between mild to moderate thrombus movement and no change. In M1 distal/M2 occlusion, marked thrombus movement was associated with improved 90-day good outcome compared with no change (70% versus 56%; adjusted odds ratio, 2.54 [95% CI, 1.21-5.51]). CONCLUSIONS: Early thrombus movement is common after intravenous alteplase. Marked thrombus migration leads to good clinical outcomes. Thrombus dynamics over time should be further evaluated in clinical trials of acute reperfusion therapy.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21019598
003      
CZ-PrNML
005      
20210830101202.0
007      
ta
008      
210728s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1161/STROKEAHA.120.029292 $2 doi
035    __
$a (PubMed)33317416
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Ohara, Tomoyuki $u Calgary Stroke Program, Hotchkiss Brain Institute, Departments of Clinical Neurosciences and Radiology, Cumming School of Medicine, University of Calgary, Canada (T.O., B.K.M., M.H., M.N., A.A.-S., M.G., M.D.H., M.A., A.M.D.) $u Department of Neurology, Kyoto Prefectural University of Medicine, Kyoto, Japan (T.O.)
245    10
$a Thrombus Migration and Fragmentation After Intravenous Alteplase Treatment: The INTERRSeCT Study / $c T. Ohara, BK. Menon, FS. Al-Ajlan, M. Horn, M. Najm, A. Al-Sultan, J. Puig, D. Dowlatshahi, AI. Calleja Sanz, SI. Sohn, SH. Ahn, AY. Poppe, R. Mikulik, N. Asdaghi, TS. Field, A. Jin, T. Asil, JM. Boulanger, F. Letteri, S. Dey, JW. Evans, M. Goyal, MD. Hill, M. Almekhlafi, AM. Demchuk, for INTERRSeCT Study Investigators
520    9_
$a BACKGROUND AND PURPOSE: There is interest in what happens over time to the thrombus after intravenous alteplase. We study the effect of alteplase on thrombus structure and its impact on clinical outcome in patients with acute stroke. METHODS: Intravenous alteplase treated stroke patients with intracranial internal carotid artery or middle cerebral artery occlusion identified on baseline computed tomography angiography and with follow-up vascular imaging (computed tomography angiography or first run of angiography before endovascular therapy) were enrolled from INTERRSeCT study (Identifying New Approaches to Optimize Thrombus Characterization for Predicting Early Recanalization and Reperfusion With IV Alteplase and Other Treatments Using Serial CT Angiography). Thrombus movement after intravenous alteplase was classified into complete recanalization, thrombus migration, thrombus fragmentation, and no change. Thrombus migration was diagnosed when occlusion site moved distally and graded according to degrees of thrombus movement (grade 0-3). Thrombus fragmentation was diagnosed when a new distal occlusion in addition to the primary occlusion was identified on follow-up imaging. The association between thrombus movement and clinical outcome was also evaluated. RESULTS: Among 427 patients in this study, thrombus movement was seen in 54% with a median time of 123 minutes from alteplase administration to follow-up imaging, and sub-classified as marked (thrombus migration grade 2-3 + complete recanalization; 27%) and mild to moderate thrombus movement (thrombus fragmentation + thrombus migration grade 0-1; 27%). In patients with proximal M1/internal carotid artery occlusion, marked thrombus movement was associated with a higher rate of good outcome (90-day modified Rankin Scale, 0-2) compared with mild to moderate movement (52% versus 27%; adjusted odds ratio, 5.64 [95% CI, 1.72-20.10]). No difference was seen in outcomes between mild to moderate thrombus movement and no change. In M1 distal/M2 occlusion, marked thrombus movement was associated with improved 90-day good outcome compared with no change (70% versus 56%; adjusted odds ratio, 2.54 [95% CI, 1.21-5.51]). CONCLUSIONS: Early thrombus movement is common after intravenous alteplase. Marked thrombus migration leads to good clinical outcomes. Thrombus dynamics over time should be further evaluated in clinical trials of acute reperfusion therapy.
650    _2
$a intravenózní podání $7 D061605
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a arteria carotis interna $7 D002343
650    _2
$a stenóza arteria carotis $x diagnostické zobrazování $x farmakoterapie $7 D016893
650    _2
$a CT angiografie $7 D000072226
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a fibrinolytika $x aplikace a dávkování $x terapeutické užití $7 D005343
650    _2
$a lidé $7 D006801
650    _2
$a infarkt arteria cerebri media $x diagnostické zobrazování $x farmakoterapie $7 D020244
650    _2
$a intrakraniální trombóza $x diagnostické zobrazování $x farmakoterapie $7 D020767
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a reperfuze $7 D015424
650    _2
$a cévní mozková příhoda $x diagnostické zobrazování $x farmakoterapie $7 D020521
650    _2
$a trombolytická terapie $7 D015912
650    _2
$a tkáňový aktivátor plazminogenu $x aplikace a dávkování $x terapeutické užití $7 D010959
650    _2
$a počítačová rentgenová tomografie $7 D014057
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Menon, Bijoy K $u Calgary Stroke Program, Hotchkiss Brain Institute, Departments of Clinical Neurosciences and Radiology, Cumming School of Medicine, University of Calgary, Canada (T.O., B.K.M., M.H., M.N., A.A.-S., M.G., M.D.H., M.A., A.M.D.)
700    1_
$a Al-Ajlan, Fahad S $u King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia (F.S.A.-A.)
700    1_
$a Horn, MacKenzie $u Calgary Stroke Program, Hotchkiss Brain Institute, Departments of Clinical Neurosciences and Radiology, Cumming School of Medicine, University of Calgary, Canada (T.O., B.K.M., M.H., M.N., A.A.-S., M.G., M.D.H., M.A., A.M.D.)
700    1_
$a Najm, Mohamed $u Calgary Stroke Program, Hotchkiss Brain Institute, Departments of Clinical Neurosciences and Radiology, Cumming School of Medicine, University of Calgary, Canada (T.O., B.K.M., M.H., M.N., A.A.-S., M.G., M.D.H., M.A., A.M.D.)
700    1_
$a Al-Sultan, Abdulaziz $u Calgary Stroke Program, Hotchkiss Brain Institute, Departments of Clinical Neurosciences and Radiology, Cumming School of Medicine, University of Calgary, Canada (T.O., B.K.M., M.H., M.N., A.A.-S., M.G., M.D.H., M.A., A.M.D.)
700    1_
$a Puig, Josep $u IDI-IDIBGI, Dr Josep Trueta University Hospital, Girona, Spain (J.P.)
700    1_
$a Dowlatshahi, Dar $u Department of Medicine, University of Ottawa and Ottawa Hospital Research Institute, Canada (D.D.)
700    1_
$a Calleja Sanz, Ana I $u Department of Neurology, Universitary Clinical Hospital of Valladolid, Spain (A.I.C.-S.)
700    1_
$a Sohn, Sung-Il $u Department of Neurology, Keimyung University, Daegu, Republic of Korea (S.-I.S.)
700    1_
$a Ahn, Seong H $u Gwangju Institute of Science and Technology, Republic of Korea (S.H.A.)
700    1_
$a Poppe, Alexandre Y $u Department of Neurosciences, University of Montreal, Canada (A.Y.P.)
700    1_
$a Mikulik, Robert $u International Clinical Research Center, Department of Neurology, St Anne's University Hospital, Masaryk University, Brno, Czech Republic (R.M.)
700    1_
$a Asdaghi, Negar $u University of Miami, FL (N.A.)
700    1_
$a Field, Thalia S $u Division of Neurology, University of British Columbia, Vancouver, British Columbia, Canada (T.S.F.)
700    1_
$a Jin, Albert $u Department of Medicine (Neurology), Queen's University, Kingston, Ontario, Canada (A.J.)
700    1_
$a Asil, Talip $u Bezmialem Vakif Univesitesi Noroloji, Istanbul, Turkey (T.A.)
700    1_
$a Boulanger, Jean-Martin $u Charles LeMoyne Hospital, Greenfield Park, QC, Canada (J.-M.B.)
700    1_
$a Letteri, Federica $u Istituto Don Calabria, IRCCS Sacro Cuore Hospital, Negrar, Italy (F.L.)
700    1_
$a Dey, Sadanand $u AMRI, Mukundapur, Kolkata, India (S.D.)
700    1_
$a Evans, James W $u Gosford Hospital, Gosford, NSW, Australia (J.W.E.)
700    1_
$a Goyal, Mayank $u Calgary Stroke Program, Hotchkiss Brain Institute, Departments of Clinical Neurosciences and Radiology, Cumming School of Medicine, University of Calgary, Canada (T.O., B.K.M., M.H., M.N., A.A.-S., M.G., M.D.H., M.A., A.M.D.)
700    1_
$a Hill, Michael D $u Calgary Stroke Program, Hotchkiss Brain Institute, Departments of Clinical Neurosciences and Radiology, Cumming School of Medicine, University of Calgary, Canada (T.O., B.K.M., M.H., M.N., A.A.-S., M.G., M.D.H., M.A., A.M.D.)
700    1_
$a Almekhlafi, Mohammed $u Calgary Stroke Program, Hotchkiss Brain Institute, Departments of Clinical Neurosciences and Radiology, Cumming School of Medicine, University of Calgary, Canada (T.O., B.K.M., M.H., M.N., A.A.-S., M.G., M.D.H., M.A., A.M.D.)
700    1_
$a Demchuk, Andrew M $u Calgary Stroke Program, Hotchkiss Brain Institute, Departments of Clinical Neurosciences and Radiology, Cumming School of Medicine, University of Calgary, Canada (T.O., B.K.M., M.H., M.N., A.A.-S., M.G., M.D.H., M.A., A.M.D.)
710    2_
$a for INTERRSeCT Study Investigators
773    0_
$w MED00010659 $t Stroke $x 1524-4628 $g Roč. 52, č. 1 (2021), s. 203-212
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33317416 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830101202 $b ABA008
999    __
$a ok $b bmc $g 1690427 $s 1140044
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 52 $c 1 $d 203-212 $e 20201215 $i 1524-4628 $m Stroke $n Stroke $x MED00010659
GRA    __
$p CIHR $2 Canada
LZP    __
$a Pubmed-20210728
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace